You are here

fibrodysplasia ossificans progressiva

FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease

BioSpace

Thu, 08/17/23 - 10:08 am

fibrodysplasia ossificans progressiva

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

BioSpace

Mon, 08/14/23 - 11:29 am

Revance Therapeutics

fibrodysplasia ossificans progressiva

cervical dystonia

Huntington's disease

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

BioSpace

Fri, 07/28/23 - 11:46 am

fibrodysplasia ossificans progressiva

Santhera Pharmaceuticals

FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP

Globe Newswire

Wed, 06/28/23 - 10:27 pm

fibrodysplasia ossificans progressiva

FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm

BioSpace

Tue, 06/27/23 - 10:19 am

fibrodysplasia ossificans progressiva

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

Fierce Biotech

Sun, 03/19/23 - 01:34 pm

fibrodysplasia ossificans progressiva

BioCryst leaves ultra-rare bone disease efforts in hands of Ipsen, Regeneron with discontinuation

Fierce Biotech

Tue, 11/1/22 - 11:00 am

fibrodysplasia ossificans progressiva

Halloween adcomm postponed as FDA seeks more Ipsen data on ultra rare disorder drug candidate

Endpoints

Tue, 10/25/22 - 11:09 pm

fibrodysplasia ossificans progressiva

Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns

Bloomberg

Fri, 12/6/19 - 09:50 am

fibrodysplasia ossificans progressiva

osteochondromas

With clear FDA path, Clementia raises $70.2M

BioCentury

Wed, 10/31/18 - 09:52 am

Clementia Pharmaceuticals

fibrodysplasia ossificans progressiva